Printer Friendly

MediGene receives United States patents for the treatment of cancer.

German-American biopharmaceutical company MediGene AG (Munich, Germany; 49-89-85653324) announced that the United States Patent and Trademark Office has issued two patents (United States Patent 6,340,673 and 6,379,674) that are exclusively licensed to MediGene. The patents cover specific oncolytic herpes simplex viruses (HSV) for the treatment of cancer either by the direct killing of tumor cells, or by eliciting anti-tumor immune responses.

The HSV technology offers a novel approach to treat cancer and is a key technology in MediGene's product portfolio. The company has two oncolytic HSVs in clinical development: G207 is in clinical phase 1b/2 for the treatment of glioma and NV1020 is in phase 1 for the treatment of liver metastases of colorectal cancer.

"These new patents strengthen MediGene's leading position in the field of oncolytic herpes viruses and will enhance the commercial potential of our HSV-based drugs," explained Dr. Peter Heinrich, CEO of MediGene. Analysts predict an annual sales potential of over EUR 300 million for G207 for the treatment of brain cancer and a potential of over EUR 200 million for NV1020 to treat liver metastases of colorectal cancer. Additionally, G207 and NV1020 may be developed for other cancer indications.

The HSV technology is based on the potential of genetically engineered herpes simplex viruses to infect and destroy tumor cells without harming the surrounding healthy cells. MediGene's HSV patent portfolio consists of 19 issued and 12 pending patents in the United States and is protected by further patents in major world markets.

MediGene AG is a publicly quoted, internationally orientated biopharmaceutical company with a wholly owned subsidiary MediGene, Inc in San Diego. MediGene has the most extensive and most mature drug development pipeline in Germany and is one of the leading European biopharmaceutical companies. Besides broad platform technologies, the company has 6 therapeutic products in clinical development and registration.
COPYRIGHT 2002 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Comment:MediGene receives United States patents for the treatment of cancer.
Publication:BIOTECH Patent News
Article Type:Brief Article
Geographic Code:4EUGE
Date:Jul 1, 2002
Words:307
Previous Article:Discovery Genomics and AngioGenetics joint venture.
Next Article:TKT announces victory over Amgen in Dynepo.
Topics:


Related Articles
Repligen issued broad United States patent for use of secretin in the treatment of autism.
University of Texas awarded patent for use of P53 gene in combination with DNA damaging agents utilizing any type of delivery system.
Calydon announces issuance of three patents for technologies that destroy cancer tumors, including prostate cancer.
Introgen's anti-cancer therapy in combination with established cancer treatments awarded patent.
GlycoDesign receives patent allowance for cancer drug.
BioCurex receives patent allowance for cancer detection and treatment.
Key patent obtained for Introgen's Phase 3 product.
GeneMax obtains immunotherapy patent.
Oncolytics Biotech obtains patent covering treatment of ras-mediated proliferative disorders.
Oregon Health & Science University issued vitamin D tumor patent.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters